Brief: Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD
01/12/2025 12:42
Dec 1 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS PRESENTS PHASE 3 PLAN FOR ZERVIMESINE (CT1812) IN ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE Source text: ID:nGNX2ZWCTH Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB